LILRB4 CAR T-cells

LILRB4 CAR T-cells are an investigational chimeric antigen receptor (CAR) T-cell therapy targeting Leukocyte Immunoglobulin-Like Receptor B4 (LILRB4), also known as ILT3. LILRB4 is an inhibitory immunoreceptor containing tyrosine-based inhibition motifs (ITIMs) that is highly expressed on malignant plasma cells in multiple myeloma (MM) and monocytic acute myeloid leukemia (AML), while maintaining low expression in most healthy tissues. The CAR-T construct, often utilizing a 4-1BB costimulatory domain and a CD3ζ signaling domain, is designed to recognize LILRB4-positive cells and induce potent cytotoxic activity. Beyond direct cell killing, targeting LILRB4 may overcome the immunosuppressive microenvironment created by the receptor's natural function as a negative immune regulator. Developed by researchers at institutions including the Moffitt Cancer Center and UT Southwestern, this therapy is being explored as a potential treatment for high-risk MM and other LILRB4-expressing hematologic malignancies.

Other names

ILT3 CAR-T cellsILT-3 CAR-T cellsILT 3 CAR-T cellsLILRB4-targeted CAR T-cellsLILRB-4-targeted CAR T-cellsLILRB 4-targeted CAR T-cellsanti-LILRB4 CAR-T cellsanti-LILRB-4 CAR-T cellsanti-LILRB 4 CAR-T cells